Top Leaders of Liquid Biopsy Market and Business Strategies
According to the new market research Liquid Biopsy Market is expected to reach $2,047.9 Million by 2022 from an estimated $715.7 Million in 2017, at a CAGR of 23.4%.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350
The
key factors driving the growth of this market include increasing
prevalence of cancer, initiatives undertaken by government and global
health organizations, increasing preference for non-invasive procedures,
technological advancement to augment market revenues, rising emphasis
on personalized medicine, and availability of funding for liquid biopsy
R&D.
The liquid biopsy market is a consolidated market with a
large number of companies offering liquid biopsy instruments and
accessories. In 2016, QIAGEN N.V. (Netherlands), Roche Diagnostics (US),
and Illumina, Inc. (US) dominated the liquid biopsy market.
The
key players in the global liquid biopsy market are QIAGEN N.V.
(Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US),
Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic
Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc.
(US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc.
(US), RainDance Technologies, Inc. (US), and MDx Health SA (US).
Illumina
ranked third in the market. The company provides sequencing and
array-based solutions for genetic analysis. The company develops,
manufactures, and markets integrated systems and life science tools for
the analysis of genetic variation and biological function. The company
operates in the market through its spinoff company “GRAIL Inc.”
Roche
Diagnostics ranked second in the liquid biopsy market. Roche
Diagnostics focuses on the discovery, manufacturing, and marketing of
medical devices used to screen, diagnose, and monitor therapies. The
company operates in the liquid biopsy market through its molecular
diagnostics segment.
QIAGEN is the leading player in the liquid
biopsy market in 2016. The company is a global provider of
sample-to-insight solutions that aids in the transformation of
biological samples into molecular insights. The company operates through
its two business segments, namely, instruments and consumables &
related products.
Request Free Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=13966350
North
America is expected to account for the largest share of the liquid
biopsy market in 2017, followed by Europe. A number of factors such as
the easy accessibility and high adoption of advanced diagnostic
technologies (such as PCR and NGS) among healthcare professionals,
rising prevalence of cancer in the US and Canada, technological
advancements in liquid biopsy products, and growing public and private
funding to support research activities in the field of liquid biopsy are
aiding market growth in the region.
Comments
Post a Comment